Caribou Biosciences vs TScan Therapeutics
CRBU and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and TCRX compare
Caribou Biosciences is the larger company, worth 3.8 times as much as TScan Therapeutics ($37.8M against $9.8M).
Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus 2.2% for TScan Therapeutics).
Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −1655% at TScan Therapeutics.
Caribou Biosciences scores higher on the StockData Score (9 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $37.8M | $9.8M |
| Share price | $0.353 | $0.145 |
| Change, 1 year | −82.2% | −87.2% |
| Change, 5 years | −98.0% | −98.3% |
| Beta (5Y) | 1.36 | 2.20 |
| Employees | 97 | 142 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× | 1.4× (better) |
| P/B | 0.4× | 0.1× (better) |
| FCF yield | −253% (better) | −1204% |
| Fair value | $1.29 | $1.36 |
| Margin of safety | 72.6% | 89.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | 2.2% |
| Revenue growth, 5Y average | −2.0% | 56.9% (better) |
| Profitability | ||
| Operating margin | −1091% (better) | −1695% |
| Net margin | −1030% (better) | −1655% |
| FCF margin | −954% (better) | −1666% |
| Return on equity | −78.3% (better) | −95.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.47 (better) |
| Interest coverage | – | −43.2× |
| Current ratio | 6.49 (better) | 3.37 |
| Altman Z-score | −7.46 | −6.31 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | −64.0% | – |
| Shareholder yield | −64.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 53.5% |
| Held by insiders | 5.7% | 32.8% |
| Insider net buying, 12 months | −$47.5K | $146K (better) |
| Short interest, % of float | 14.7% | 4.4% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.